Insmed INSM · NASDAQ
$95.29 -1.02% (-$0.98)
Summary
38 / 100 · Bulios Score
What speaks for it
- Revenue grew by 35% a year over the last 3 years.
- Analysts expect revenue to grow by 196% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- It missed profit estimates 6 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 30% a year over 5 years. Over the last 3 years it grew by 35% a year. For the next fiscal year analysts expect revenue to grow by 196%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $875.3M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 33
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $197 is 107% above today's price. 92% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
- UNITED STATES 75%
- Non-US 25%
Reportable Segment brings in 100% of revenue.
Segments in detail